Cjc 1295 Research Peptide
The CJC 1295 research peptide is a synthetic tetrasubstituted analog of growth hormone-releasing hormone (GHRH) developed to evaluate growth hormone (GH) axis dynamics and tissue repair pathways in preclinical models. By binding pituitary GHRH receptors, it stimulates endogenously mediated GH release and sustained insulin-like growth factor 1 (IGF-1) expression. PX1 Research provides analytical-grade CJC-1295 verified via HPLC and mass spectrometry strictly for in vitro and laboratory research applications.
Quick answer
The CJC 1295 research peptide is a synthetic tetrasubstituted analog of growth hormone-releasing hormone (GHRH) developed to evaluate growth hormone (GH) axis dynamics and tissue repair pathways in preclinical models. By binding pituitary GHRH receptors, it stimulates endogenously mediated GH release and sustained insulin-like growth factor 1 (IGF-1) expression. PX1 Research provides analytical-grade CJC-1295 verified via HPLC and mass spectrometry strictly for in vitro and laboratory research applications.
Key takeaways
- [CJC-1295](/research-peptides/cjc-1295-no-dac) is a modified 29-amino acid peptide derivative representing the functional catalytic core of naturally occurring human growth hormone-releasing hormone (GHRH 1-29).
- At the cellular level, [CJC-1295](/research-peptides/cjc-1295-no-dac) functions as a selective agonist at the GHRH receptor, a Class B G-protein-coupled receptor (GPCR) predominantly expressed on somatotroph cells in the anterior pituitary gland.
- In animal models, administration of GHRH analogs like [CJC-1295](/research-peptides/cjc-1295-no-dac) has been shown to elevate circulating baseline GH and IGF-1 levels without eliminating the intrinsic pulsatile secretion pattern characteristic of physiological pituitary function.
- When designing comparative endocrine assays, researchers frequently contrast GHRH analogs with ghrelin receptor agonists (GHRPs) or shorter GHRH fragments.
Molecular Structure and Biochemical Overview
CJC-1295 is a modified 29-amino acid peptide derivative representing the functional catalytic core of naturally occurring human growth hormone-releasing hormone (GHRH 1-29). The original endogenous peptide exhibits a short biological half-life in laboratory assays due to rapid enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV) between the Alanine-2 and Aspartic Acid-3 residues. To enhance stability during experimental protocols, structural modifications were introduced at specific positions: D-Alanine at position 2, Glutamine at position 8, Alanine at position 15, and Leucine at position 27.
These strategic substitutions create a tetrasubstituted sequence—frequently referred to in literature as Modified GRF 1-29—that resists proteolytic degradation while maintaining high affinity for the GHRH receptor. In its conjugated form with Drug Affinity Complex (DAC), a maleimide derivative is appended to the C-terminus, allowing covalent binding to serum albumin in animal models. This structural variance fundamentally shifts the clearance kinetics, making the cjc 1295 research peptide a vital tool for studying prolonged endocrine signaling versus acute pulsatile hormone dynamics.
Mechanism of Action: GHRH Receptor Binding and Downstream Cascades
At the cellular level, CJC-1295 functions as a selective agonist at the GHRH receptor, a Class B G-protein-coupled receptor (GPCR) predominantly expressed on somatotroph cells in the anterior pituitary gland. Upon binding, the peptide activates the heterotrimeric Gs protein subunit, stimulating membrane-bound adenylate cyclase. This enzyme converts intracellular adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP), triggering downstream activation of protein kinase A (PKA).
The PKA pathway phosphorylates the cAMP response element-binding protein (CREB), which translocates to the nucleus to induce transcription of the growth hormone gene. Simultaneously, intracellular calcium influx is mediated via L-type voltage-gated calcium channels, promoting the exocytosis of stored growth hormone vesicles. Downstream, released growth hormone interacts with hepatic GH receptors to stimulate the transcription and systemic secretion of insulin-like growth factor 1 (IGF-1), establishing the primary axis through which tissue remodeling, nitrogen retention, and cellular proliferation assays are investigated.
Preclinical Literature: Tissue Repair and Metabolic Assays
In animal models, administration of GHRH analogs like CJC-1295 has been shown to elevate circulating baseline GH and IGF-1 levels without eliminating the intrinsic pulsatile secretion pattern characteristic of physiological pituitary function. Preclinical rodent studies demonstrate that sustained elevation of IGF-1 enhances protein translation in skeletal muscle tissue via the Akt/mTOR signaling cascade, facilitating research into muscle wasting, sarcopenia, and cellular hypertrophic pathways.
Furthermore, preclinical investigations into musculoskeletal wound healing reveal accelerated fibroblast migration and collagen synthesis when local tissue cultures are exposed to downstream IGF-1 induced by GHRH receptor agonists. Metabolic research models utilizing GHRH analogs also exhibit increased lipolysis in adipocyte assays, driven by hormone-sensitive lipase (HSL) activation. Researchers interested in broader neuroprotective or cardiovascular endocrine mechanisms utilize these compounds within established growth hormone-releasing hormone peptides experimental frameworks.
Comparative Analysis: CJC-1295, Ipamorelin, Tesamorelin, and Sermorelin
When designing comparative endocrine assays, researchers frequently contrast GHRH analogs with ghrelin receptor agonists (GHRPs) or shorter GHRH fragments. While CJC-1295 target-selectively engages the GHRH receptor to drive physiological GH release, compounds operating through distinct pathways provide critical comparative control groups in laboratory research.
For instance, combining CJC-1295 with a ghrelin receptor agonist such as the ipamorelin research guide peptide reveals synergistic amplification of GH release without significant elevations in prolactin or cortisol baseline metrics. Conversely, tesamorelin research peptide features a hexenoyl moiety attached to the N-terminal of GHRH, optimized for specific lipid metabolic models, whereas sermorelin laboratory peptide retains the native 1-29 sequence without tetrasubstitution, exhibiting a significantly shorter biological half-life. Evaluating these distinct biochemical profiles across our broader catalog of research peptides allows investigator groups to tailor experimental parameters precisely.
Structural Variations: CJC-1295 with DAC vs. Modified GRF 1-29 (No DAC)
A critical distinction in laboratory literature involves the presence or absence of the Drug Affinity Complex (DAC). CJC-1295 with DAC includes an added lysine linker paired with a reactive maleimide-propionyl group. In vivo animal models demonstrate that this maleimide group selectively binds to the Cys34 amino acid residue of circulating serum albumin. This irreversible covalent bond protects the peptide core from renal filtration and enzymatic cleavage, extending the functional half-life to several days in rodent and non-human primate models.
In contrast, CJC-1295 without DAC—properly termed Modified GRF 1-29—lacks the reactive linker. It exhibits an extended half-life relative to native sermorelin (approximately 30 minutes versus 8-12 minutes in preclinical assays) but does not bind serum albumin. Researchers selecting between these formulations typically utilize Modified GRF 1-29 for studying acute, pulsatile pituitary release, whereas CJC-1295 with DAC is selected for studies investigating continuous, chronic exposure to elevated baseline GHRH signaling.
Laboratory Reconstitution and Solubilization Protocol
To ensure molecular integrity during in vitro assays, lyophilized CJC-1295 powder must be handled according to strict laboratory protocols. Prior to reconstitution, vials should be allowed to equilibrate to ambient room temperature (20°C to 25°C) to prevent moisture condensation upon opening or stopper piercing. Lyophilized peptides are hydrophobic or hydrophilic depending on sequence charge, but CJC-1295 readily dissolves in sterile laboratory-grade solvents.
Reconstitution is typically performed using Bacteriostatic Water (containing 0.9% benzyl alcohol) or sterile normal saline (0.9% NaCl), depending on assay compatibility. The diluent should be introduced slowly down the glass wall of the vial using a gentle liquid transfer technique; direct forceful stream impact onto the lyophilized cake must be avoided to prevent mechanical shearing of the peptide chain. Swirl the vial with gentle rotational movements until complete dissolution is observed. Vortexing or vigorous mechanical agitation is strongly discouraged as it induces aggregation and secondary structural denaturation.
Chemical Stability and Storage Guidelines
Lyophilized CJC-1295 supplied by PX1 Research remains stable at -20°C for up to 24 months from the date of synthesis. Long-term storage at -80°C is recommended for multi-year archive preservation, avoiding repeated freeze-thaw cycles that destabilize the peptide sequence. Exposure to direct ultraviolet light, ambient thermal radiation, and atmospheric oxygen should be minimized to prevent oxidative degradation of sensitive amino acid residues such as methionine and tryptophan.
Once reconstituted into aqueous solution, the peptide exhibits reduced stability. Reconstituted CJC-1295 solutions must be stored under refrigeration at 2°C to 8°C and utilized within 28 days when preserved with bacteriostatic agents. Unpreserved sterile aqueous solutions should be used immediately or aliquoted into single-use microcentrifuge tubes and frozen at -20°C to prevent degradation and microbial contamination in analytical assays.
Quality Assurance: Verification by HPLC, ESI-MS, and Endotoxin Testing
Data accuracy in preclinical research depends entirely on the purity and mass verification of reagent compounds. Impurities, peptide truncations, or residual synthesis solvents can confound biological assays, skew cell culture viability, and introduce unaccounted variable factors. PX1 Research enforces rigorous quality control protocols on every synthesized lot of CJC-1295.
Purity is quantitatively determined using Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) with UV detection at 214 nm, ensuring a target purity profile of ≥98.0%. Molecular identity is independently verified using Electrospray Ionization Mass Spectrometry (ESI-MS), confirming the precise monoisotopic mass and sequence distribution. Furthermore, because bacterial lipopolysaccharides interfere with cell receptor signaling and immune responses, every batch undergoes chromogenic Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain below strict laboratory research thresholds (<0.01 EU/mg).
Sourcing USA-Manufactured Research Peptides from PX1 Research
PX1 Research is committed to advancing scientific inquiry by supplying domestic research institutions, university laboratories, and biotechnology organizations with verified, analytical-grade compounds. All peptides are manufactured within state-of-the-art facilities compliant with Good Manufacturing Practice (GMP) standards, ensuring exact lot-to-lot consistency and structural precision.
Every product shipped from our California and Arizona fulfillment centers includes a comprehensive, lot-specific Certificate of Analysis (COA) issued by an independent ISO 17025 accredited laboratory. Orders placed Monday through Friday receive same-day dispatch, maintaining temperature-controlled logistics to safeguard peptide stability. Academic institutions and corporate laboratories seeking high-volume requisitions are encouraged to establish a dedicated bulk research account to access specialized procurement support and batch reservation protocols.
Frequently Asked Questions
What is the primary GHRH receptor target of CJC-1295 in laboratory models?
CJC-1295 acts as a selective agonist at the GHRH receptor on anterior pituitary somatotrophs, activating the cAMP/PKA intracellular signaling cascade to induce growth hormone transcription and release.
What is the structural difference between CJC-1295 with DAC and Modified GRF 1-29?
CJC-1295 with DAC contains a C-terminal maleimide group that covalently binds to circulating serum albumin in animal models, extending its half-life to several days. Modified GRF 1-29 lacks the DAC moiety, resulting in a shorter half-life of approximately 30 minutes in preclinical assays.
How is the purity of CJC-1295 verified at PX1 Research?
Every lot undergoes Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) to ensure ≥98% purity, paired with Electrospray Ionization Mass Spectrometry (ESI-MS) to confirm exact molecular mass.
What are the endotoxin limits for PX1 Research peptides?
All peptide batches are screened using LAL chromogenic assays to confirm endotoxin levels are maintained below <0.01 EU/mg, preventing cell culture toxicity or immunological artifacts in research settings.
What reconstituted diluent is recommended for CJC-1295 in long-term assays?
Bacteriostatic Water (0.9% benzyl alcohol) is recommended for multi-dose laboratory assays stored at 2°C–8°C for up to 28 days. Sterile 0.9% NaCl saline can be used for immediate single-use applications.
How should lyophilized CJC-1295 be stored prior to reconstitution?
Lyophilized CJC-1295 should be kept sealed at -20°C for standard storage or -80°C for long-term archiving, protected from ambient moisture, heat, and direct light.
Can CJC-1295 be used in human therapeutic or clinical protocols?
No. CJC-1295 provided by PX1 Research is strictly designated for laboratory in vitro and preclinical research use only. It is not intended for human consumption, clinical diagnostic protocols, or therapeutic administration.
Where are PX1 Research peptides manufactured and shipped from?
All PX1 Research compounds are synthesized in USA-based facilities adhering to cGMP protocols and shipped directly from our inventory hubs in California and Arizona with same-day dispatch Monday through Friday.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.